AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 21, 2023
Moderna CEO Stephane Bancel told AFP his company’s experimental vaccine against melanoma could be available in as little as two years, in what would amount to a landmark step against the most serious form of skin cancer. Globally there were an estimated 325,000 new melanoma cases and 57 ,000 deaths from the disease in 2020.
Pharmaceutical Technology
DECEMBER 21, 2023
Genevoyager has announced the opening of contract development and manufacturing organisation facility to manufacture gene therapy products.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
DECEMBER 21, 2023
Ahead of a Phase 3 readout that could come next year, the pharma is paying $130 million in upfront and near-term cash for rights to the retinitis pigmentosa treatment that it didn’t already own.
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 21, 2023
In order to streamline the National Accreditation Board for Hospitals and Healthcare Providers (NABH) helpdesk and complaints redressal process, the Quality Council of India (QCI) and all its boards have introduced an innovative solution for addressing concerns promptly and transparently through “Quality Setu”.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
DECEMBER 21, 2023
The drug, acquired via a deal with ImmunoGen, was the most advanced experimental medicine in the French pharma’s pipeline.
Pharma Times
DECEMBER 21, 2023
The condition affects around 270,935 people in England and 16,090 people in Wales - News - PharmaTimes
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
DECEMBER 21, 2023
Bowel cancer is currently the third most common type of cancer in England - News - PharmaTimes
Bio Pharma Dive
DECEMBER 21, 2023
Under pressure from the activist investor, BioMarin will add more independent directors and set up an operational review committee.
Pharmaceutical Technology
DECEMBER 21, 2023
Discover a groundbreaking method to treat cancer using a combination of mitochondrial and Bcl-2 inhibitors. Learn more about this patent's innovative approach.
Fierce Pharma
DECEMBER 21, 2023
As Vertex Pharmaceuticals and CRISPR Therapeutics lay the groundwork for the launch of their CRISPR-based gene-editing therapy Casgevy, one doctor who treats sickle cell disease patients is already | As Vertex Pharmaceuticals and CRISPR Therapeutics lay the groundwork for the launch of their world-first CRISPR-based gene therapy Casgevy, one doctor who treats sickle cell disease patients is already seeing strong demand.
Pharmaceutical Technology
DECEMBER 21, 2023
Diakine-DK210 (EGFR) is under clinical development by Deka Biosciences and currently in Phase I for Pancreatic Cancer.
Fierce Pharma
DECEMBER 21, 2023
Big Pharma companies have often talked about the major opportunities that await in China. | Big Pharma companies have often talked about the major opportunities that await in China. But as price cuts play out and internal priorities shift, multinational companies are reworking their business models in the country.
Pharmaceutical Technology
DECEMBER 21, 2023
BI-1701963 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Metastatic Colorectal Cancer.
Fierce Pharma
DECEMBER 21, 2023
Two years ago, with a favorable ruling and a slap-on-the | A favorable ruling two years ago had Servier hoping that its decades-long litigation surrounding weight-loss pill Mediator was finally over. But an appeal from prosecutors now leaves the company facing a hefty penalty.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
DECEMBER 21, 2023
Sudo plans to advance two TYK2 candidates into clinical testing next year for the treatment of autoimmune and neurologic conditions.
pharmaphorum
DECEMBER 21, 2023
NICE backs NHS use of digital COPD rehab programmes, myCOPD and SPACE for COPD, as an alternative to face-to-face consultations
Pharmaceutical Technology
DECEMBER 21, 2023
The FDA released an updated guidance for developing Covid-19 monoclonal antibody treatments for EUAs as variants evolve.
Fierce Pharma
DECEMBER 21, 2023
Along with a new CEO, BioMarin will head into 2024 with three new board directors and a new strategy review committee after settling with activist investor Elliott Investment Management. | Elliott Investment Management is one of BioMarin's largest investors with a stake worth more than $1 billion. The three new independent directors include a former Lilly exec and ImmunoGen's CEO.
Pharmaceutical Technology
DECEMBER 21, 2023
Cadonilimab is under clinical development by Akeso and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer).
pharmaphorum
DECEMBER 21, 2023
Sanofi ends development of CEACAM5-targeting ADC tusamitamab ravtansine after it fails a phase 3 trial in non-small cell lung cancer (NSCLC)
Pharmaceutical Technology
DECEMBER 21, 2023
Cadonilimab is under clinical development by Akeso and currently in Phase II for Small-Cell Lung Cancer.
Fierce Pharma
DECEMBER 21, 2023
Ionis Pharmaceuticals and AstraZeneca are wrapping up the year with a much-anticipated present from the FDA: an approval for the companies’ transthyretin amyloidosis (ATTR) drug Wainua. | The approval in hereditary transthyretin-mediated amyloid polyneuropathy, which affects around 40,000 to 50,000 patients globally, sets the stage for a potential label expansion down the line to treat the broader transthyretin amyloid cardiomyopathy patient population.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
DECEMBER 21, 2023
BT-8009 is under clinical development by Bicycle Therapeutics and currently in Phase II for Fallopian Tube Cancer.
pharmaphorum
DECEMBER 21, 2023
Lilly partners with Fauna Bio in $494m deal to see if a hibernating squirrel's genomics could unlock new obesity drug targets.
Pharmaceutical Technology
DECEMBER 21, 2023
Despite approvals in Europe and Japan, the FDA rejected the oral drug, citing a lack of substantial evidence for treatment effectiveness.
pharmaphorum
DECEMBER 21, 2023
An organisation representing the interests of patients with prostate cancer has published a manifesto ahead of the EU elections next year, calling for more screening for the disease in EU member states.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
DECEMBER 21, 2023
Calliditas Therapeutics has received the US FDA approval for Tarpeyo to treat adult primary immunoglobulin A nephropathy (IgAN) patients.
pharmaphorum
DECEMBER 21, 2023
Indivior has secured a $111 million BARDA supply contract in the US for its Opvee intranasal therapy for treating opioid overdose
Pharmaceutical Technology
DECEMBER 21, 2023
GSK has signed an exclusive licence agreement for Hansoh Pharma’s B7-H3-targeting ADC, HS-20093, for potential treatment of solid tumours.
Intouch Solutions
DECEMBER 21, 2023
Recently, three of our creative leaders at EVERSANA INTOUCH had the honor of participating in a webinar hosted by Cannes Lions, exploring the theme of “Health and the Health-Conscious Consumer.” This insightful session featured Susan Perlbachs, Chief Creative Officer; Nick Capanear, Managing Director, Executive Creative Director; and Ivan Blotta, Group Creative Director, Head of Art.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
245 
Let's personalize your content